Mass spectrometric signatures of the blood plasma metabolome for disease diagnostics
- Authors:
- Petr G. Lokhov
- Elena E. Balashova
- Anna A. Voskresenskaya
- Oxana P. Trifonova
- Dmitry L. Maslov
- Alexander I. Archakov
View Affiliations
Affiliations: Institute of Biomedical Chemistry, Moscow 119121, Russia
- Published online on: November 24, 2015 https://doi.org/10.3892/br.2015.548
-
Pages:
122-126
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
In metabolomics, a large number of small molecules can be detected in a single run. However, metabolomic data do not include the absolute concentrations of each metabolite. Generally, mass spectrometry analyses provide metabolite concentrations that are derived from mass peak intensities, and the peak intensities are strictly dependent on the type of mass spectrometer used, as well as the technical characteristics, options and protocols applied. To convert mass peak intensities to actual concentrations, calibration curves have to be generated for each metabolite, and this represents a significant challenge depending on the number of metabolites that are detected and involved in metabolome‑based diagnostics. To overcome this limitation, and to facilitate the development of diagnostic tests based on metabolomics, mass peak intensities may be expressed in quintiles. The present study demonstrates the advantage of this approach. The examples of diagnostic signatures, which were designed in accordance to this approach, are provided for lung and prostate cancer (leading causes of mortality due to cancer in developed countries) and impaired glucose tolerance (which precedes type 2 diabetes, the most common endocrinology disease worldwide).
View References
1
|
Trifonova O, Lokhov P and Archakov A:
Postgenomics diagnostics: Metabolomics approaches to human blood
profiling. OMICS. 17:550–559. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Gowda GA, Zhang S, Gu H, Asiago V,
Shanaiah N and Raftery D: Metabolomics-based methods for early
disease diagnostics. Expert Rev Mol Diagn. 8:617–633. 2008.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Katajamaa M and Oresic M: Data processing
for mass spectrometry-based metabolomics. J Chromatogr A.
1158:318–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lokhov PG, Dashtiev MI, Moshkovskii SA and
Archakov AI: Metabolite profiling of blood plasma of patients with
prostate cancer. Metabolomics. 6:156–163. 2009. View Article : Google Scholar
|
5
|
Lokhov PG, Kharybin ON and Archakov AI:
Diagnosis of lung cancer based on direct-infusion electrospray mass
spectrometry of blood plasma metabolites. Int J Mass Spectrom.
309:200–205. 2012. View Article : Google Scholar
|
6
|
Lokhov PG, Trifonova OP, Maslov DL and
Archakov AI: Blood plasma metabolites and the risk of developing
lung cancer in Russia. Eur J Cancer Prev. 22:335–341. 2013.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Lokhov PG, Trifonova OP, Maslov DL,
Balashova EE, Archakov AI, Shestakova EA, Shestakova MV and Dedov
II: Diagnosing impaired glucose tolerance using direct infusion
mass spectrometry of blood plasma. PLoS One. 9:e1053432014.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Koulman A, Tapper BA, Fraser K, Cao M,
Lane GA and Rasmussen S: High-throughput direct-infusion ion trap
mass spectrometry: A new method for metabolomics. Rapid Commun Mass
Spectrom. 21:421–428. 2007. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Lin L, Yu Q, Yan X, Hang W, Zheng J, Xing
J and Huang B: Direct infusion mass spectrometry or liquid
chromatography mass spectrometry for human metabonomics? A serum
metabonomic study of kidney cancer. Analyst. 135:2970–2978. 2010.
View Article : Google Scholar : PubMed/NCBI
|